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Podoplanin-positive cells are a hallmark of encapsulating
peritoneal sclerosis
Abstract
BACKGROUND: Encapsulating peritoneal sclerosis (EPS) and simple peritoneal sclerosis are
important complications of long-term peritoneal dialysis (PD). Podoplanin is expressed by mesothelial
cells and lymphatic vessels, which are involved in inflammatory reactions in the peritoneal cavity.
METHODS: We studied 69 peritoneal biopsies from patients on PD (n = 16), patients with EPS (n = 18)
and control biopsies taken at the time of hernia repair (n = 15) or appendectomy (n = 20).
Immunohistochemistry was performed to localize podoplanin. Additionally, markers of endothelial
cells, mesothelial cells, myofibroblasts (smooth muscle actin), proliferating cells, and double labelling
for smooth muscle actin/podoplanin were used on selected biopsies. RESULTS: Podoplanin was present
on the endothelium of lymphatic vessels in the submesothelial fibrous tissue and on mesothelial cells. In
patients on PD and in biopsies with appendicitis, the mesothelial cells demonstrated a cuboidal
appearance and circumferential podoplanin staining, with gaps between the cells. The number of
lymphatic vessels was variable, but prominent at sites of fibrosis. In patients with EPS, a diffuse
infiltration of podoplanin-positive cells with a fibroblastic appearance was present in 15 out of 18
biopsies. This pattern was focally present in 3 out of 16 on PD and none in the 35 controls. The
podoplanin-positive cells did not express the endothelial marker or the mesothelial marker (calretinin).
CONCLUSIONS: EPS is characterized by a population of podoplanin and smooth muscle actin
double-positive cells. Podoplanin might be a suitable morphological marker supporting the diagnosis
and might be involved in the pathogenesis of EPS.
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Abstract
Background. Encapsulating peritoneal sclerosis (EPS)
and simple peritoneal sclerosis are important complica-
tions of long-term peritoneal dialysis (PD). Podoplanin is
expressed by mesothelial cells and lymphatic vessels,
which are involved in inflammatory reactions in the peri-
toneal cavity.
Methods. We studied 69 peritoneal biopsies from patients
on PD (n = 16), patients with EPS (n = 18) and control bi-
opsies taken at the time of hernia repair (n = 15) or append-
ectomy (n = 20). Immunohistochemistry was performed to
localize podoplanin. Additionally, markers of endothelial
cells, mesothelial cells, myofibroblasts (smooth muscle
actin), proliferating cells, and double labelling for smooth
muscle actin/podoplanin were used on selected biopsies.
Results. Podoplanin was present on the endothelium of
lymphatic vessels in the submesothelial fibrous tissue
and on mesothelial cells. In patients on PD and in biopsies
with appendicitis, the mesothelial cells demonstrated a
cuboidal appearance and circumferential podoplanin stain-
ing, with gaps between the cells. The number of lymphatic
vessels was variable, but prominent at sites of fibrosis. In
patients with EPS, a diffuse infiltration of podoplanin-
positive cells with a fibroblastic appearance was present
in 15 out of 18 biopsies. This pattern was focally present
in 3 out of 16 on PD and none in the 35 controls. The
podoplanin-positive cells did not express the endothelial
marker or the mesothelial marker (calretinin).
Conclusions. EPS is characterized by a population of po-
doplanin and smooth muscle actin double-positive cells.
Podoplanin might be a suitable morphological marker sup-
porting the diagnosis and might be involved in the patho-
genesis of EPS.
Keywords: encapsulating peritoneal sclerosis; EPS; peritoneal dialysis;
podoplanin
Introduction
Encapsulating peritoneal sclerosis (EPS) is an uncommon
but potentially life-threatening complication of peritoneal
dialysis (PD) [1]. The key factors for the diagnosis of
EPS are clinical symptoms of bowel obstruction, a typical
radiological picture and extensive thickening of the peri-
toneal membrane (resulting in cocooning of the bowel)
[2]. Morphological features of EPS are mesothelial de-
nudation, peritoneal fibroblast swelling, interstitial fibro-
sis, angiogenesis with increased numbers of capillaries
and mononuclear cell infiltration [3,4]. The peritoneal
membrane is affected by fibrin deposits, which may lead
to adherences and permanent scarring [2].
Simple sclerosis on the other hand is characterized by
increased thickening of the peritoneal membrane, loss of
peritoneal function with high transporter status, but no
clinical symptoms of bowel obstruction [5,6]. EPS can
be differentiated from simple sclerosis by the deposition
of fibrin and the increased thickness of the degenerative
compact zone. Angiogenesis, vasculopathy, new mem-
brane formation and fibrosis did not distinguish between
simple sclerosis and EPS [7]. The histological picture is
therefore relatively unspecific, particularly in early stages,
and morphological markers are currently not available.
Podoplanin (also known as aggrus, hT1α or M2A re-
cognized by the antibody D2-40) is a member of a family
of type-1 transmembrane sialomucin-like glycoproteins
[8]. The protein has an extracellular domain (with abun-
© The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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dant Ser and Thr residues as potential O-glycosylation
sites), a single transmembrane portion and a short cyto-
plasmic tail [9]. As a glycoprotein, it can bind chemokines
and modulate inflammatory reactions. Podoplanin was ori-
ginally described to be lost in rat puromycin nephritis and
was named according to the loss of foot processes in this
model (flat feet in latin, pes planus) [10]. Later it was found
to be a good marker for lymphatic endothelial cells, but it is
also expressed by peritoneal mesothelial cells [11]. As
podoplanin can bind chemokines, it may modulate the in-
flammatory milieu (on mesothelial cells and on lymphatic
vessels) and therefore might be involved in the injury
process of both simple sclerosis and EPS [12]. Podoplanin
can be detected by the antibody D2-40, which is suitable for
routine staining of formalin-fixed and paraffin-embedded
tissues. This antibody enables the localization of mesothe-
lial cells, and cells of mesothelial origin in combination with
markers of endothelial origin.
The goal of this study was to localize podoplanin in
peritoneal biopsies from patients on PD with and without
clinical signs of EPS.
Materials and methods
Study population
Sixty-nine tissue samples with different peritoneal pathological states
were either selected from the files of the Department of Pathology or ran-
domly from a database of 220 patients. All patients had given informed
consent for their tissue to be used for research purposes. Patients with
appendicitis were selected randomly. Biopsies were submerged in buf-
fered formalin and embedded in paraffin following routine protocols.
The biopsies were incorporated into paraffin blocks so that sections were
cut in a right angle to the surface. Histological features were scars in the
submucosal layer and small to moderate lymphoplasmacellular infiltra-
tions in the tunica propria and/or subserosal layer. For purposes of com-
parison with study patients, 15 specimens were selected randomly from
patients who had undergone hernia repairs (direct or indirect). Peritoneal
biopsies from patients on PD were also included (n = 16). The tissue was
taken from the visceral peritoneum, from areas located at least 10 cm
away from the peritoneal catheter entry side. Indications for surgery were
herniotomy, leakage or catheter removal because of switching to haemo-
dialysis. In addition, we collected tissues from all patients with EPS from
our Department of Nephrology or sent for additional investigations to the
Department of Pathology (n = 18).
For diagnosis, we used criteria stated by Nakamoto [13]: stage 1 (pre-
EPS period) characterized by loss of ultrafiltration, development of high
transport state, hypoproteinaemia, bloody dialysate, ascites and calcifica-
tion of peritoneum; stage 2 (inflammation period), increases in C-reactive
peptide level, white blood cell count, fever, weight loss, appetite loss and
diarrhoea; stage 3 (encapsulating or progressive period), disappearance of
signs of inflammation and appearance of signs of ileus (nausea, vomiting,
abdominal pain, constipation, abdominal mass and ascites); and stage 4
(ileus or complete period), anorexia, complete ileus and abdominal mass.
Our patients with EPS were in stages 3 and 4. Peritoneal biopsies were
formalin-fixed and paraffin-embedded following routine protocols. All
patients in the EPS group underwent preoperative CT scans; intraopera-
tive findings were documented.
Immunohistochemistry
Immunohistochemistry was performed as previously described [14]. De-
waxed and rehydrated tissue sections were incubated in 3% hydrogen per-
oxide (to block endogenous peroxidases). The antigen retrieval was
performed in an autoclave oven, using the antigen retrieval solution (Vector,
Burlingame, CA). The primary antibodieswere applied for 1 h or overnight.
Incubation with biotinylated secondary reagents (Vector) for 30 min was
followed by the ABC reagent (Vector). 3′3′Diaminobenzidine (DAB,
Sigma, Taufkirchen, Germany) with metal enhancement (resulting in a
black colour product) was used as a detection system.
A monoclonal mouse antihuman podoplanin antibody (D2-40, Signet
Laboratories, Dedham, MA) was used on all biopsies [15,16]. As controls
we used human tonsils, including the replacement of the antibody by di-
luent of isotype-matched control antibodies. These controls did not dem-
onstrate positive staining (not illustrated). All sections were evaluated by
an observer blinded to the specimen’s diagnosis. The following monoclo-
nal mouse antibodies were used on selected biopsies on consecutive sec-
tions: anti-CD31 (JC70A, DakoCytomation, Glostrup, Denmark) for
endothelial cells, anti-calretinin (Dak Calret 1, DakoCytomation, Glostrup,
Denmark) and anti-smoothmuscle actin (1A4, DakoCytomation, Glostrup,
Denmark) for myofibroblasts and anti-KI-67 (2D3, InnoGenex, San
Ramon, CA) for proliferating cells.
The appearance of podoplanin-positive infiltrating cells was scored as
follows by an observer blinded to the diagnosis of the biopsies: 0: positive
podoplanin staining on lymphatics and mesothelial cells, but not on single
cells with fibroblastic appearance; 1: focal accumulation of podoplanin-
positive cells with fibroblastic appearance; 2: diffuse accumulation of
podoplanin-positive cells with fibroblastic appearance.
Immunofluorescence
Double immunofluorescence for D2-40 and smooth muscle actin was per-
formed similarly as previously described [15]. Another antigen retrieval
with microwave treatment was performed between the two staining proce-
dures. Both primary antibodieswere replaced by isotype control antibodies.
Statistics
To calculate specificity, sensitivity and predictive values, a contingency
table was created (InStat® software, Version 3.05, Intuitive Software
for Science, San Diego, CA). The row/column association was tested
by the Fisher’s exact test. The means of scores were compared by the
non-parametric Kruskal–Wallis test. A P < 0.05 was considered to be
statistically significant.
Results
Podoplanin in normal peritoneal biopsies and in
inflammatory peritoneal lesions
The clinical features of the study population were sum-
marized in Table 1. In order to describe the distribution
of D2-40-positive cells in the abdominal cavity of patients
not involved in PD, we studied peritoneal biopsies taken
during hernia repair (n = 15, Figure 1A–C). The mesothe-
lial cell layer was positive for D2-40 (as previously de-
scribed) and helped to define the peritoneal surface of
the peritoneal biopsies (Figure 1A, B; [17]). Even in these
normal control biopsies, the mesothelial cell layer was
commonly lost, most likely due to the tissue handling.
When the mesothelium was conserved, it demonstrated a
flat appearance (Figure 1B). Podoplanin was predominantly
localized on the apical side of the mesothelial cells and at
times intercellularly (lateral sides, Figure 1B). A low num-
ber of lymphatic vessels were present in the submesothelial
fibrotic tissue and the adjacent fat tissue (Figure 1C). These
lymphatic vessels were commonly associated with larger
arteries and veins (Figure 1C). Overall, the number of
D2-40-positive vessels in the submesothelial tissue and
the adjacent fat tissue was low.
Biopsies taken at the time of appendectomy were used
as an example of an inflammatory lesion in the abdominal
cavity (n = 20). In the majority of biopsies, the mesothe-
lium demonstrated a plump, cuboidal appearance with
gaps between the mesothelial cells (Figure 1D, E). D2-40
was present circumferentially on these activated mesothelial
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Table 1. Clinical data of study patients
Variable Normal peritoneum Appendicitis PD EPS
n 15 20 16 18
Age (years; mean ± SD) 58.4 ± 19.9 40.4 ± 35.6 49.5 ± 15.1 45.7 ± 13.5
PD—duration in months 24 ± 25.7 76 ± 37.2 (** vs PD)
Peritonitis 5 in 384 months 1:77 34 in 1,017 months 1:30 (* vs PD)
PDF
Neutral 2/16 6/18
Acidic 4/16 2/18
Both or N.D. 10/16 11/18
Icodextrin 1/6 10 N.D. 8/9 10 N.D. (* vs PD)
Diabetes 0/15 0/20 5/16 3/18
Smoker 4/12 2 N.D. 7/19 1 N.D. 2/15 1 N.D. 7/14 4 N.D.
Hypertension 4/20 2/20 7/16 11/18
Hb (g/dL ± SD [13–18]) 13.8 ± 1.7 13.7 ± 1.1 10.8 ± 1.9 10.0 ± 4.1
Leukocytes (G/L ± SD [4.0–11.3]) 8.0 ± 3.0 10.4 ± 2.9 7.2 ± 2.0 9.1 ± 4.04
Phosphate (mmol/L [0.68–1.68]) N.D. N.D. 1.78 ± 0.67 1.50 ± 0.54
Calcium (mmol/L [1.90–2.70]) 2.32 ± 0.12 2.35 ± 0.09 2.37 ± 0.22 2.24 ± 0.47
PTH (pmol/L [1.1–7.3]) N.D. N.D. 19.1 ± 17.3 27.2 ± 25.38
Urea-N (mg/dL [10–25]) N.D. N.D. 68.38 ± 40.68 40.09 ± 17.04 (* vs PD)
Creatinine (mg/dL [0.5–1.4]) 1.4 ± 1.7 1.0 ± 0.3 8.3 ± 4.0 7.0 ± 1.90
PD, peritoneal dialysis; EPS, encapsulating peritoneal sclerosis; PDF, peritoneal dialysis fluid; Hb, haemoglobin; N.D., not determined; PTH, parathy-
roid hormone, *: P < 0.05, **: P < 0.01.
Fig. 1. Expression of podoplanin in controls. Immunohistochemistry was performed on tissue sections from peritoneal biopsies taken at the time of
hernia repair (A–C) or during appendectomy (D, E) with the monoclonal antibody D2-40 against podoplanin (orig. ×100 in D; ×250 in A, C; ×400 in
B, E). The normal mesothelium cells were positive for podoplanin on the apical and intercellular region of the relatively flat mesothelial cells.
Lymphatic vessels were present close to larger arteries in the submesothelial interstitial tissue (arrow). In biopsies from patients with appendicitis,
the mesothelial cells were cuboid, with gaps between the cells (arrowhead, lymphatic vessels are labelled by arrows in D, E). This activated
mesothelium commonly demonstrated circumferential podoplanin staining.
Podoplanin in encapsulating peritoneal sclerosis 1035
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cells (Figure 1E). Focal accumulation of lymphatic vessels
was present at sites of inflammatory cell accumulations.
Expression of podoplanin in peritoneal biopsies in patients
on PD
Sixteen biopsies from patients on PD were included in the
study (Figure 2A, B). The transporter status was available
in seven patients prior to biopsies, of whom 1 was low, 3
were low average, 1 high average and 1 high. In two biop-
sies, the mesothelium was found to be preserved. In both
cases, the mesothelium had a cuboidal appearance, similar
to what was described for the patients with appendicitis
(Figure 2B). The number of D2-40-positive vessels was
quite variable ranging from a single positive vessel per
biopsy to a very prominent accumulation of D2-40-positive
vessels in the thickened peritoneal membrane (Figure 2A).
Three biopsies demonstrated a diffuse infiltration of podo-
planin-positive cells.
Expression of podoplanin in EPS
Eighteen biopsies from patients on PD with clinical signs
of EPS (radiological picture, symptoms of intestinal ob-
Fig. 2. Podoplanin in patients on peritoneal dialysis. Immunohistochemistry was performed on tissue sections from peritoneal biopsies taken from
patients on PD (A–B) or on PD with signs of EPS (C–E) with the monoclonal antibody D2-40 against podoplanin (orig. ×100 in A, C, D; ×250 in B; ×
400 in E). A prominent number of lymphatic vessels were present in the submesothelial interstitial tissue (arrows in A). A single layer of mesothelial
cells was present on the surface of the biopsies, but with a cuboidal appearance (arrow in B) and with gaps between the cells (arrowhead in B). The
morphological picture of EPS demonstrated the absence of a mesothelial cell layer on the surface (arrow in E). A high number of podoplanin-positive
cells with the morphological appearance of fibroblasts are embedded in the extracellular matrix of EPS (C–E).
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struction) were included (Figure 2C–E, Figure 3). The find-
ings in the CT scans were calcifications (4/18), cocooning
(11/18), peritoneal thickening (11/18), ascites after cessa-
tion of PD (7/18) and bowel dilatation (7/18). All patients
underwent surgery and showed the typical features of EPS
(ascites and fluid loculation, peritoneal thickening, adhe-
sions, bowel dilatation and cocooning with thickening of
the visceral peritoneum). The transporter status prior to
stopping PD was in five patients, high average, and in two
patients, high.
In the biopsies, the mesothelial cells on the surface
were absent in all biopsies (Figure 2E, arrow). The podo-
planin staining demonstrated a striking pattern with a high
number of positive cells embedded in the sclerotic matrix
(Figure 2E, Figure 3A). These podoplanin-positive cells had
the morphological appearance of fibroblasts (Figure 2E). To
further define the involved cell types, consecutive sections
of four biopsies were further studied for the expression of
CD31 (as an endothelial marker, Figure 3C), calretinin (a
marker of mesothelial cells, Figure 3D) and smooth muscle
actin (for myofibroblasts, Figure 3B, F). CD31 was positive
on the endothelium of arteries and veins as expected, but the
podoplanin-positive ‘infiltrating’ cells were CD31 negative
(Figure 3C). Scattered lymphatic vessels were CD31 posi-
tive (as this marker does not discriminate between blood and
lymphatic endothelial cells). Therefore, the podoplanin-
positive cell population is unlikely of endothelial origin.
Calretinin was only found to be expressed by a small num-
ber of cells close to the surface, but the vast majority of
podoplanin-positive cells were negative (Figure 3D). The
diffuse pattern of these cells mirrored the staining pattern
for smooth muscle actin (Figure 3A, B, E, F). KI-67 (a cell
proliferation marker) was expressed by scattered cells with
focal accumulations of these cells (not illustrated).
The pattern of smooth muscle actin-positive myofibro-
blasts mirrored the distribution of podoplanin-positive
cells; therefore, we performed immunofluorescence to
confirm the double-positive cells (Figure 4). Smooth
muscle actin-positive myofibroblasts embedded in the fi-
brotic tissue (Figure 4A, D) were also positive for podopla-
nin (Figure 4B, E). An overlay of the two reaction patterns
is illustrated in Figure 4 (C, F). The smooth muscle actin-
positive cells of vessel walls were podoplanin negative
(Figure 4D, E). On the other hand, the podoplanin-positive
Fig. 3. Characteristics of the podoplanin-positive cells in EPS. Immunohistochemistry was performed on tissue sections from peritoneal biopsies taken
from patients with EPS with a monoclonal antibody against podoplanin (A, E), smooth muscle actin (B, F), CD31 (C) or against calretinin (D, orig. ×
100 in A–D; ×250 in E, F). A high number of D2-40 and smooth muscle actin-positive cells were present in a similar pattern of distribution (A, B and
E, F). The vast majority of the D2-40-positive cells were CD31 and calretinin negative (C, D). Some CD31-positive vessels (arrowheads in C) and some
calretinin-positive cells (arrow in D) were present.
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lymphatic vessels were smooth muscle actin negative
(Figure 4A, B).
In Figure 5A, the results are illustrated according to the
time on PD and the number of peritonitis episodes. There is
an overlap of the time on PD between patients with EPS and
the patients on PD of ~50 months. The PD patients with the
pattern were not the ones with long time on PD (Figure 5A).
The fibrotic zone was significantly thicker in the patients
with EPS [as compared to the patients on PD (P < 0.05) and
the control biopsies (P < 0.001)]. The biopsies from patients
Fig. 4. Double immunofluorescence for podoplanin and smooth muscle actin in EPS. Double immunofluorescence was performed on biopsies with
EPS for smooth muscle actin (A, D) and podoplanin (with the monoclonal antibody D2-40, (B, E), orig. ×400). The overlay with the nuclear
counterstain (DAPI) is illustrated in (C) and (F). Please note the podoplanin-positive lymphatic vessels (arrows in B), which are smooth muscle
actin negative. The ‘heart’ illustrated in F is a larger vein with a single layer of smooth muscle cells (D), which are podoplanin negative (E).
Fig. 5. Description of the time on PD, fibrosis and podoplanin scores. (A) The study population is illustrated according to the time on PD, the number
of peritonitis episodes and the podoplanin scores. Please note that there is an overlap of ~50 months between the patients with EPS and without EPS,
but the patients on PD with the pattern fall within the first 40 months of dialysis (w/o, without). (B) The thickness of the fibrosis zone was measured in a
blinded fashion (*P < 0.05, **P < 0.01, ***P < 0.001). (C) The mean podoplanin scores (± SEM) are illustrated (**P < 0.01, ***P < 0.001).
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on PD also demonstrated thickening of the submesothelial
fibrotic zone (P < 0.01 as compared to control biopsies).
The podoplanin scores were significantly higher in EPS,
as compared to patients on PD without EPS and controls
(Figure 5C). An area of podoplanin-positive cells embed-
ded in a fibrotic matrix was present in 15 out of 18 biopsies
in patients with EPS, in 3 out of 16 patients on PD without
signs of EPS, but none in the 35 controls. The three patients
on PD who demonstrated a diffuse presence of podoplanin-
positive cells were treated for 4, 5 and 22 months.
In this retrospectively collected biopsies, the staining pat-
tern was significantly associated with EPS (P < 0.0001). It
resulted in a sensitivity of 0.83 (95% confidence interval
0.59–0.96) and a specificity of 0.94 (95% confidence inter-
val 0.84–0.99). The positive predictive value was 0.83
(95% confidence interval 0.5857–0.9642) and the nega-
tive predictive value 0.94 (95% confidence interval
0.8377–0.9877). The likelihood ratio was 14.2.
Discussion
The main finding of this study was the discovery of a po-
doplanin and smooth muscle actin double-positive cell
type, which forms the majority of cells in the biopsies from
patients with EPS. The diagnosis of EPS must be based on
a typical clinical, radiologic picture. Unfortunately, the
histological picture is not specific, and markers differenti-
ating between simple sclerosis and EPS are not available at
the moment.
In a direct comparison of PD-associated simple sclerosis
and EPS, the morphological differences were found to be a
significantly thicker sclerosis zone in EPS (750 versus
45 μm), fibrin deposition, fibroblast swelling, the presence
of inflammation, vascular alterations, up-regulation of vas-
cular endothelial growth factor and the presence of tissue
calcification [18–21]. The thickness of sclerosis demon-
strated a bimodal distribution without intermediate stages
[18]. In EPS, the fibrin deposition is accompanied by a de-
creased number of mast cells and a decrease in mast cell
tryptase [4]. Mast cell tryptase has a strong fibrinogenoly-
tic activity [22]. With our study, we add a new marker to
the morphological evaluation of biopsies from patients
with EPS. The majority of cells in the sclerosis zone ex-
pressed podoplanin in combination with the typical myofi-
broblast marker (smooth muscle actin). Morphologically,
these cells represent fibroblasts. The diffuse appearance
of podoplanin-positive cells separated the majority of cases
with EPS from simple sclerosis. In contrast to other mar-
kers previously used (e.g. smooth muscle actin), which
was found to be commonly present, podoplanin-positive
cells with a fibroblastic appearance were only found in a
minority of patients on PD without signs of EPS (3 out of
16) [20]. None of the biopsies taken during hernia repair,
appendicitis and in uraemic patients before PD was in-
itiated (n = 9, not illustrated) demonstrated the podoplanin
pattern. Therefore, this pattern had a good specificity and
negative predictive value. We are currently planning a larger
multicenter study to include a higher number of patients.
Particularly early cases of EPS need to be compared with
late cases of simple sclerosis (matched for the time on PD).
From the clinical point of view, simple sclerosis and
EPS are two different entities, the latter with an aggressive
course with life-threatening bowel obstruction [21]. It is
still unclear whether there is a subclinical transition phase
(early EPS; [21]). In our study, three patients had no clin-
ical signs of EPS, but the morphological appearance and
the podoplanin-positive pattern at least focally. One patient
presented with ascites and an early form of EPS seems
possible (also we have no data to confirm this). In one pa-
tient, the biopsy was taken close to the catheter where fibro-
sis might be present. It is currently unclear whether the
podoplanin-positive pattern is a reflection of an early dis-
ease course or a risk factor for the development of EPS.
On the other hand, three biopsies in the EPS group did
not demonstrate the typical pattern of podoplanin-positive
cells. Follow-up was available in only one podoplanin-
negative patient where all other diagnostic criteria con-
firmed EPS. Whether this is due to a sampling error or a
technical problem with the staining technique is currently
not clear. Further studies are clearly needed including EPS
samples from different sources to evaluate the clinical use-
fulness of D2-40 in routine material.
The source of the double-positive cells remains un-
defined. In detailed electron-microscopic studies, the heal-
ing process in the rat abdominal cavity was evaluated [23].
Following physical injury, the new mesothelium developed
from subperitoneal connective tissue cells. These cells
demonstrated subcellular similarities with primitive mes-
enchymal cells and with fibroblasts in the subperitoneal
stroma. The combination of smooth muscle actin and
podoplanin expression might indicate a cell type with an
intermediate phenotype between myofibroblasts and differ-
entiated mesothelial cells. In the studies by Raftery, the mes-
enchymal cells finally differentiated into mesothelial cells
[23]. When the podoplanin-positive cells would be a cell
population attempting to rebuild the mesothelial integrity,
the absence of a basement membrane might prevent the dif-
ferentiation, keeping the cells in an immature fibroblastic
and profibrotic cell type in EPS. The denudation of the peri-
toneal cavity could be the driving force for the process.
The transition of mesothelial cells into a fibroblastic
phenotype (called epithelial mesenchymal transition) has
recently found a lot of attention [24–27]. A part of the fi-
broblasts in the sclerotic zone might be derived from
mesothelial cells. This might explain why these cells still
express podoplanin as a mesothelial cell marker. As the
transition of mesothelial cells into fibroblasts has been de-
monstrated to be an early event involved in simple scle-
rosis [25], this hypothesis would not be consistent with
our data, as the majority of patients on PD but without
signs of EPS did not demonstrate double-positive cells.
As illustrated in Figure 5A, the PD patients without EPS
but with the pattern all have a time on PD lower than
50 months. Therefore, the podoplanin pattern was not just
associated with time on PD.
Conclusion
In summary, we describe a new cell marker combination in-
volved in patients with EPS. Podoplaninmight turn out to be
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useful in routine morphological evaluation as well as a driv-
ing force of this devastating condition. We formulated sev-
eral new hypotheses which can now be tested in vitro and in
vivo.
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